Integrating Epidermal Growth Factor Receptor–Targeted Therapies into Platinum-Based Chemotherapy Regimens for Newly Diagnosed Non–Small-Cell Lung Cancer
References (57)
- et al.
Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 cells squamous carcinoma cells
J Biol Chem
(1994) - et al.
Epidermal growth factor receptor expression correlates with a poor prognosis in completely resected non-small-cell lung cancer
Ann Oncol
(2004) - et al.
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Lancet
(2005) - et al.
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation
Clin Lung Cancer
(2007) - et al.
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Ann Oncol
(2008) - et al.
A randomized multicenter phase III study of Cetuximab in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
J Thorac Oncol
(2007) - et al.
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
Ann Oncol
(2006) - et al.
Preclinical and clinical evaluations of ABXEGF, a fully human anti-epidermal growth factor receptor antibody
Int J Radiat Oncol Biol Phys
(2004) - et al.
American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-smallcell lung cancer guideline: update 2003
J Clin Oncol
(2004) - et al.
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
J Natl Cancer Inst
(2007)
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in nonsmall-cell lung cancer
J Clin Oncol
New molecularly targeted therapies for lung cancer
J Clin Invest
Targeting the epidermal growth factor receptor for cancer therapy
J Clin Oncol
Anti tumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
Cancer Res
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
Eur Respir J
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
J Clin Oncol
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
JAMA
Erlotinib in previously treated non-small-cell lung cancer
N Engl J Med
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
Clin Cancer Res
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
Clin Cancer Res
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models
Anticancer Drugs
Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 1
J Clin Oncol
Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a phase III trial—INTACT 2
J Clin Oncol
TRIBUTE: a phase III trial of Erlotinib Hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
J Clin Oncol
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
J Clin Oncol
Combining the anti-EGFR agent gefitinib with chemotherapy in non–small-cell lung cancer: How do we go from INTACT to Impact?
J Clin Oncol
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non–small cell lung cancer cells
Clin Cancer Res
Cited by (18)
Predictive markers in the adjuvant therapy of non-small cell lung cancer
2011, Lung CancerCitation Excerpt :Thus, KRAS mutations do not appear to predict benefit from adjuvant treatment with gefitinib. EGFR-TKIs such as gefitinib and erlotinib have demonstrated efficacy in patients with advanced NSCLC [67,68], particularly in those who harbor activating mutations in the EGFR TK domain of their tumors [69–71]. These mutations were first identified in 2004 and shown to confer sensitivity to EGFR TKIs.
Monoclonal antibodies against EGFR in non-small cell lung cancer
2011, Critical Reviews in Oncology/HematologyCitation Excerpt :According to a meta-analysis based on five adjuvant chemotherapy trials, the survival gain achieved by cisplatin-based protocols is absolute 5% at 5 years [7]. Customized chemotherapy [8] and targeted therapies are current strategies to improve the outcome of systemic therapy in patients with NSCLC [9–14]. Targeted therapies focus on the inhibition of growth factor receptor systems, angiogenesis or both [9–14].
Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: An update
2015, Current Opinion in OncologyNovel drugs against non-small-cell lung cancer
2014, Current Opinion in Oncology
This summary includes discussion of investigational and/or unlabeled uses of drugs, including the use of gefitinib/chemotherapy, erlotinib/chemotherapy, cetuximab, matuzumab, and panitumumab in non–small-cell lung cancer.
Dr Pirker has served as a paid consultant, served on a Speaker's Bureau, or been on the Advisory Board of Roche and Amgen.
Ms Minar has no relevant relationships to disclose.
Dr Filipits has no relevant relationships to disclose.